We found that CDN4 only responded in combined immunotherapy with anti-PD-1/CTLA-4, which may contribute to the dual blockade of PD-1/CTLA-4 increasing effector T-cell activity to enhance tumor suppression38. This evidence concerns the gene CTLA4 and neoplasm.